Home › Funds › Sanofi › ATOS

Sanofi position in ATOS

Attovia Therapeutics Inc · Health Care

Sanofi reported holding 1,082,855 shares of ATOS (Attovia Therapeutics Inc) in its Q3 2026 13F filing — a position valued at US$18.6M, representing 2.95% of its reported portfolio and ranking #10 among its reported holdings. Sanofi first reported this position in Q3 2026.

Latest position (Q3 2026)1.08M sh
Reported value held$18.56M
Portfolio Weight2.95%
First reportedQ3 2026
Last changeNew
Updated2026-11-05

Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR

How Sanofi's ATOS position evolved

Sanofi first disclosed a stake in ATOS in Q3 2026 at 1,082,855 shares (US$18.6M).

Quarter by quarter

QuarterSharesValueChange
Q3 2026 1.08M $18.56M New

About ATOS and 13F data

ATOS (Attovia Therapeutics Inc) is a Health Care company. 14 other funds we track also report a position in ATOS. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ATOS

No other tracked fund reports a position in ATOS.

All ATOS fund holders →

FAQ

How long has Sanofi held ATOS?

Sanofi has disclosed ATOS holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is Sanofi's current position in ATOS?

As of Q3 2026, Sanofi holds 1.08M shares of ATOS (Attovia Therapeutics Inc), valued at $18.56M, representing 2.95% of its reported portfolio and ranking #10.

Has Sanofi been buying or selling ATOS?

In the latest 13F filing (Q3 2026), Sanofi newly opened its position in ATOS.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.